Jazz Pharmaceuticals (JAZZ) Capital Expenditures (2010 - 2026)

Jazz Pharmaceuticals' Capital Expenditures history runs 17 years deep, the most recent figure standing at $77.2 million for Q1 2026.

• In Q1 2026, Capital Expenditures changed N/A year-over-year to $77.2 million; the TTM figure through Mar 2026 stood at $136.0 million (up 300.09% YoY), while the FY2025 annual figure was $58.8 million, up 54.33% from the prior year.
• Capital Expenditures for Q1 2026 stood at $77.2 million, up from -$799.3 million in the prior quarter.
• The five-year high for Capital Expenditures was $857.3 million in Q3 2025, with the low at -$799.3 million in Q4 2025.
• The 5-year median for Capital Expenditures is $4.2 million (2022), against an average of $12.4 million.
• Peak annual rise in Capital Expenditures reached 7846.34% in 2025, while the deepest fall reached 6115.66% in 2025.
• Jazz Pharmaceuticals' Capital Expenditures stood at $4.4 million in 2022, then tumbled by 417.16% to -$13.9 million in 2023, then jumped by 195.87% to $13.3 million in 2024, then tumbled by 6115.66% to -$799.3 million in 2025, then soared by 109.66% to $77.2 million in 2026.
• Business Quant data shows JAZZ's Capital Expenditures at $77.2 million in Q1 2026, -$799.3 million in Q4 2025, and $857.3 million in Q3 2025.